Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.

Article Details

Citation

Cembala TM, Forde SC, Appadu BL, Lambert DG

Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.

Eur J Pharmacol. 2007 Aug 13;569(1-2):37-40. Epub 2007 May 22.

PubMed ID
17588565 [ View in PubMed
]
Abstract

Neuromuscular blocking drugs produce muscle weakness by interaction with nicotinic-acetylcholine receptors. Cardiovascular side effects have been reported. In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01). These data indicate that vecuronium, gallamine and pancuronium interact with an allosteric site on the muscarinic M2 receptor (located on the heart) and this may explain some of their cardiac side effects.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
AtropineMuscarinic acetylcholine receptor M2ProteinHumans
Yes
Antagonist
Details
Gallamine triethiodideMuscarinic acetylcholine receptor M2ProteinHumans
Yes
Antagonist
Details
PancuroniumMuscarinic acetylcholine receptor M2ProteinHumans
Unknown
Antagonist
Details